Osteoprotegerin CGA haplotype protection against cerebrovascular complications in anti-CCP negative patients with rheumatoid arthritis

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Genre, Fernanda ^a   López Mejías, Raquel ^a   García Bermudez, Mercedes ^b   Castañeda, Santos ^c   González Juanatey, Carlos ^d   Llorca, Javier ^e,f   Corrales, Alfonso ^a   Ubilla, Begoña ^a   Miranda Filloy, José A ^d   Pina, Trinitario ^a   Gómez Vaquero, Carmen ^g   Rodríguez Rodríguez, Luis ^h   Fernández Gutiérrez, Benjamín ^h   Balsa, Alejandro ⁱ   Pascual Salcedo, Dora ⁱ   López Longo, Francisco J ^j   Carreira, Patricia ^k   Blanco, Ricardo ^a   González Álvaro, Isidoro ^c   Martín, Javier ^b   González Gay, Miguel A ^a   more..

^a IDIVAL   (Spain)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d HOSPITAL UNIVERSITARIO LUCUS AUGUSTI   (Spain)

^e UNIVERSITY OF CANTABRIA   (Spain)

^f CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^h HOSPITAL CLÍNICO SAN CARLOS   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^k HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; OSTEOPROTEGERIN; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; TNFRSF11B PROTEIN, HUMAN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; OPG GENE; RHEUMATOID ARTHRITIS; AGED; BLOOD; CEREBROVASCULAR DISORDERS; CLINICAL TRIAL; COMPLICATION; GENETICS; MIDDLE AGED; MULTICENTER STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

ADULT; AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CEREBROVASCULAR DISORDERS; FEMALE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PEPTIDES, CYCLIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SPAIN;

EID: 84906976724     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106823     Document Type: Article

References (45)

1. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D (2012) Risk of incident cardiovascular events in patients with rheumatoid arthritis: a metaanalysis of observational studies. Ann Rheum Dis 71:1524-1529.
2. Goodson N, Marks J, Lunt M, Symmons D (2005) Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 64:1595-1601.
3. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, et al. (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107:1303-1307.
4. Del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44:2737-2745.
5. Peters MJ, van Halm VP, Voskuyl AE, Smulders YM, Boers M, et al. (2009) Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 61:1571-1579.
6. van Halm VP, Peters MJ, Voskuyl AE, Boers M, Lems WF, et al. (2009) Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 68:1395-1400.
7. Wolfe F, Freundlich B, Straus WL (2003) Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 30:36-40.
8. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Piñeiro A, Garcia-Porrua C, et al. (2007) HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 57:125-132.
9. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J (2005) Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 35:8-17.
10. Dessein PH, Joffe BI, Veller MG, Stevens BA, Tobias M, et al. (2005) Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 32:435-442.
11. García-Bermúdez M, López-Mejías R, Genre F, Castañeda S, González-Juanatey C, et al. (2013) SMAD3 rs17228212 gene polymorphism is associated with reduced risk to cerebrovascular accidents and subclinical atherosclerosis in anti-CCP negative Spanish rheumatoid arthritis patients. PLoS One 8:e77695.
12. López-Mejías R, García-Bermúdez M, González-Juanatey C, Castañeda S, Miranda-Filloy JA, et al. (2012) NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 224:426-429.
13. Gonzalez-Gay MA, Gonzalez-Juanatey C, Piñeiro A, Garcia-Porrua C, Testa A, et al. (2005) High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 32:1219-1223.
14. Del Rincón I, Williams K, Stern MP, Freeman GL, O'Leary DH, et al. (2003) Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 48:1833-1840.
15. Rodríguez-Rodríguez L, López-Mejías R, García-Bermúdez M, González-Juanatey C, González-Gay MA, et al. (2012) Genetic markers of cardiovascular disease in rheumatoid arthritis. Mediators Inflamm 2012:574817.
16. Hofbauer LC, Schoppet M (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292:490-495.
17. Van Campenhout A, Golledge J (2009) Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 204:321-329.
18. Secchiero P, Corallini F, Beltrami AP, Ceconi C, Bonasia V, et al. (2010) An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. Atherosclerosis 210:274-277.
19. Secchiero P, Rimondi E, di Iasio MG, Agnoletto C, Melloni E, et al. (2013) C-reactive protein downregulates TRAIL expression in human peripheral monocytes via an Egr-1-dependent pathway. Clin Cancer Res 19:1949-1959.
20. Di Bartolo BA, Cartland SP, Harith HH, Bobryshev YV, Schoppet M, et al. (2013) TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL. PLoS One 8:e74211.
21. Callegari A, Coons ML, Ricks JL, Yang HL, Gross TS, et al. (2013) Bone marrow- or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification. Arterioscler Thromb Vasc Biol 33:2491-2500.
22. Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, et al. (2008) Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr (2/2) mice. Circulation 117:411-420.
23. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, et al. (2004) Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109:2175-2180.
24. Soufi M, Schoppet M, Sattler AM, Herzum M, Maisch B, et al. (2004) Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab 89:3764-3768.
25. Roshandel D, Holliday KL, Pye SR, Ward KA, Boonen S, et al. (2011) Influence of polymorphisms in the RANKL/RANK/OPG signaling pathway on volumetric bone mineral density and bone geometry at the forearm in men. Calcif Tissue Int 89:446-455.
26. Straface G, Biscetti F, Pitocco D, Bertoletti G, Misuraca M, et al. (2011) Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene, TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability. Stroke 42:3022-3028.
27. Biscetti F, Straface G, Giovannini S, Santoliquido A, Angelini F, et al. (2013) Association between TNFRSF11B gene polymorphisms and history of ischemic stroke in Italian diabetic patients. Hum Genet 132:49-55.
28. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324.
29. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, et al. (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569-2581.
30. Gonzalez-Juanatey C, Llorca J, Martin J, Gonzalez-Gay MA (2009) Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum 38:366-371.
31. Dessein PH, López-Mejias R, González-Juanatey C, Genre F, Miranda-Filloy JA, et al. (2014) Independent Relationship of Osteoprotegerin Concentrations with Endothelial Activation and Carotid Atherosclerosis in Patients with Severe Rheumatoid Arthritis. J Rheumatol 41:429-436.
32. Genre F, López-Mejías R, Miranda-Filloy JA, Ubilla B, Carnero-López B, et al. (2014) Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy. Clin Exp Rheumatol: In press.
33. Chen WJ, Rijzewijk LJ, van der Meer RW, Heymans MW, van Duinkerken E, et al. (2011) Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men. Cardiovasc Diabetol 10:67.
34. Jorsal A, Tarnow L, Flyvbjerg A, Parving HH, Rossing P, et al. (2008) Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia 51:2100-2107.
35. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R (2006) The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 47:1850-1857.
36. Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A (2006) Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 154:75-81.
37. Bjerre M (2013) Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications. Springerplus 2:658.
38. Mankoč Ramuš S, Kumše T, Globočnik Petrovič M, Petrovič D, Cilenšek I (2013) SNP rs2073618 of the osteoprotegerin gene is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes. Biomed Res Int 2013:364073.
39. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW (2005) Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 7(5):R949-958.
40. van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, et al. (2004) Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 50(7):2113-2121.
41. del Val del Amo N, Ibanez Bosch R, Fito Manteca C, Gutierrez Polo R, Loza Cortina E (2006) Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clin Exp Rheumatol 24(3):281-286.
42. Zhao H, Pfeiffer R, Gail MH (2003) Haplotype analysis in population genetics and association studies. Pharmacogenomics 4:171-178.
43. Morris RW, Kaplan NL (2002) On the advantage of haplotype analysis in the presence of multiple disease susceptibility alleles. Genet Epidemiol 23:221-233.
44. Martin ER, Lai EH, Gilbert JR, Rogala AR, Afshari AJ, et al. (2000) SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. Am J Hum Genet 67:383-394.
45. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, et al. (2000) Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 97:10483-10488.